Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO

January 3, 2023

Biotechnology

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

April 26, 2024
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

April 26, 2024
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

April 25, 2024
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

April 25, 2024